Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Blood (2023) 142 (23): 1960–1971.

https://doi.org/10.1182/blood.2023020301

Published: 2023

Includes: Supplemental data

Journal Articles

Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

Blood (2023) 142 (Supplement 1): 4641.

https://doi.org/10.1182/blood-2023-181595

Published: 2023

Journal Articles

Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Receiving Ibrutinib on the Phase 3 ASPEN Study ≥1 Year After Transitioning to Zanubrutinib

Ramon Garcia-Sanz, Roger Owen, Wojciech Jurczak, Meletios A. Dimopoulos, Helen McCarthy, Gavin Cull, Stephen Opat, Jorge J. Castillo, Marie José Kersten, Björn E. Wahlin, Sebastian Grosicki, Radha Prathikanti, Tian Tian, Heather Allewelt, Aileen Cleary Cohen, Constantine S. Tam

Blood (2023) 142 (Supplement 1): 3043.

https://doi.org/10.1182/blood-2023-174294

Published: 2023

Journal Articles

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Blood (2020) 136 (Supplement 1): 36–38.

https://doi.org/10.1182/blood-2020-137334

Published: 2020

Journal Articles

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Blood (2020) 136 (18): 2038–2050.

https://doi.org/10.1182/blood.2020006844

Published: 2020

Includes: Supplemental data

Journal Articles

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up

Judith Trotman, Stephen Opat, David Gottlieb, David Simpson, Paula Marlton, Gavin Cull, Javier Munoz, Alessandra Tedeschi, Andrew W. Roberts, John F. Seymour, Siminder Kaur Atwal, Yiling Yu, William Novotny, Eric Holmgren, Ziwen Tan, James D. Hilger, Jane Huang, Constantine S. Tam

Blood (2020) 136 (18): 2027–2037.

https://doi.org/10.1182/blood.2020006449

Published: 2020

Includes: Supplemental data

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Daniel J. DeAngelo, MD PhD, Harry P. Erba, MD PhD, Brian A Jonas, MD PhD, Michael E O'Dwyer, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Gerwin Huls, MD PhD, Jane L. Liesveld, MD, Brenda Cooper, MD, Bhavana Bhatnagar, DO, Geoffrey L. Uy, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Michael B. Armstrong, MD PhD, William E. Fogler, PhD, Mary M Chen, MD PhD, John L. Magnani, PhD, Helen M Thackray, MD, Eric J. Feldman, MD, Anjali S. Advani, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2650.

https://doi.org/10.1182/blood-2019-123816

Published: 2019

Journal Articles

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Constantine S. Tam, MBBS, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Stephen Opat, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Aichun Liu, MD, Anna M. Johnston, Weili Zhao, MD PhD, Fernando Roncolato, BMed, FRACP, FRCPA, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Wenyu Li, MD PhD, Ted Shih, PharmD, Xiaoping Zhang, MD MS, Ken Wu, PhD, Yuan Liu, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 1594.

https://doi.org/10.1182/blood-2019-125485

Published: 2019

Journal Articles

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Blood (2019) 134 (11): 851–859.

https://doi.org/10.1182/blood.2019001160

Published: 2019

Includes: Supplemental data

Journal Articles

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Devinder Gill, MD MRCP, FRCPath, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Leanne Berkahn, MD, David Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Rosemary Anne Harrup, MD, Naomi J. Mackinlay, MB BS, FRACP, FRCPA, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Xavier Badoux, MBBS, AB, FRACP, FRCPA, Oliver Giles Best, PhD BSc, Bryone Jean Kuss, PhD BMBS, FRCPA, FRACP

Blood (2018) 132 (Supplement 1): 4432.

https://doi.org/10.1182/blood-2018-99-114064

Published: 2018

Journal Articles

Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma

Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Michael Wang, MD, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Javier Munoz, MD, Tycel J. Phillips, MD, Won-Seog Kim, MD PhD, James Hilger, PhD, Jane Huang, MD, William Novotny, MD, Judith Trotman

Blood (2018) 132 (Supplement 1): 1592.

https://doi.org/10.1182/blood-2018-99-117224

Published: 2018

Journal Articles

Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (Cbl+G) As Front-Line Therapy

Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Jane A. Freeman, BA, FRACP, FRCPA, MBBS, MPhil, MSc, Xavier Badoux, MBBS, AB, FRACP, FRCPA, Richard Eek, MBCHB, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Naomi J. Mackinlay, MB BS, FRACP, FRCPA, Nicholas E. Murphy, FRCPA, MBBS, FRACP, Duncan P. Carradice, MBBS, FRCPA, FRACP, Ann C. Solterbeck, BSc(hons) MSc PhDAStat, Oliver Giles Best, PhD BSc, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Bryone J. Kuss, PhD BMBS, FRCPA, FRACP

Blood (2018) 132 (Supplement 1): 3144.

https://doi.org/10.1182/blood-2018-99-116287

Published: 2018

Journal Articles

Effect of Rituximab in Primary Central Nervous System Lymphoma - results of the Randomized Phase III HOVON 105/ALLG NHL 24 Study

Jacoline Bromberg, MD, Samar Issa, FRACP, Katerina Bukanina, Monique C Minnema, Tatjana Seute, MD, Marc Durian, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Harry C. Schouten, MD, Wendy B Stevens, MD, Josée Zijlstra, MD, Johanna W. Baars, MD PhD, Marcel Nijland, MD, Kylie Mason, MBBS,PhDFRACP,FRCPA, Aart Beeker, MD, Martin van den Bent, MD, Daphne de Jong, Prof Dr, Michael Anthony Gonzales, BSc, Jeanette K. Doorduijn, MD PhD

Blood (2017) 130 (Supplement 1): 582.

https://doi.org/10.1182/blood.V130.Suppl_1.582.582

Published: 2017

Journal Articles

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies

Gavin Cull, MB, BS, FRACP, FRCPA, Stephen Opat, FRACP, FRCPA, Judith Trotman, MBChB, FRACP, FRCPA, James Hilger, Xiaoping Zhang, Shibao Feng, PhD, Sunhee Ro, PhD, Jane Huang, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 4057.

https://doi.org/10.1182/blood.V130.Suppl_1.4057.4057

Published: 2017

Journal Articles

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma

Constantine S. Tam, MBBS, MD FRACP, FRCPA, David Simpson, MBChB, Stephen Opat, FRACP, FRCPA, Won Seog Kim, MD, Ph. D., Michael Wang, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Patrick B Johnston, MD PhD, Javier Munoz, MD, Won-Sik Lee, MD, Paula Marlton, MBBS, David Gottlieb, MBBS, MD FRACP, FRCPA, Lai Wang, PhD, Jane Huang, MD, James Hilger, Ling Xue, PhD, Sunhee Ro, PhD, Judith Trotman, FRACP

Blood (2017) 130 (Supplement 1): 152.

https://doi.org/10.1182/blood.V130.Suppl_1.152.152

Published: 2017

Journal Articles

Prognostic Factors and the Impact of Frontline Therapy in Peripheral T-Cell Lymphoma: A Multicenter Australian Study

James Anton Kuzich, MBBS, Andrew Peter Hutchison, MBBS, Kenneth Lim, MBBS, Matthew P.F. Wright, MBBS, FRCPA, FRACP, Gavin Cull, MB, BS, FRACP, FRCPA, Michael F. Leahy, FRACP,FRCPath,FRCP, David John Longstaff Joske, Dejan Radeski, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP

Blood (2017) 130 (Supplement 1): 1524.

https://doi.org/10.1182/blood.V130.Suppl_1.1524.1524

Published: 2017

Journal Articles

High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study

Constantine S. Tam, MBBS, Judith Trotman, MBChB, Stephen Opat, MD, Paula Marlton, MBBS, Gavin Cull, MBBS DM FRACP FRCPA, David Simpson, MBChB, FRACP, FRCPA, Matthew Ku, MBBS, David Ritchie, MD PhD, Emma Verner, FRACP, FRCPA, MBBS, Sumita Ratnasingam, MBBS, Mary Ann Anderson, MBBS, Peter Wood, MD FRACP, FRCPA, MBBS, Mark Kirschbaum, MD, Lai Wang, PhD, Ling Xue, Jianxin Yang, Eric Hedrick, John F Seymour, Andrew W. Roberts

Blood (2016) 128 (22): 1216.

https://doi.org/10.1182/blood.V128.22.1216.1216

Published: 2016

Journal Articles

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Bradstock Kenneth, Emma Link, DPhil, Juliana Di Iulio, BAppSc, PhD, Jeff Szer, MB, BS, FRACP, Paula Marlton, MBBS, FRCPA, FRACP, Andrew Wei, MBBS, PhD, Arno Enno, MB,BS,FRCPA, FRACP, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Ian D. Lewis, MBBS PhDFRACP FRCPA, James D'Rozario, MB BS FRACP, Luke Coyle, MBBS, FRACP, FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Philip Campbell, MB ChB FRACP FRCPA, Michael Francis Leahy, FRACP, Uwe H Hahn, MDFGCP FRCPA, Paul Cannell, MD, Campbell Tiley, MBBS,FRACP, FRCPA, Raymond M. Lowenthal, MD FRACP, FRCP, John Moore, MBBS, MD FRACP , FRCPA, Kimberly Cartwright, FRACP,MDFRCPA, Ilona Cunningham, John Taper, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Andrew W. Roberts, MBBS PhD, Warwick John Benson, Mark S Hertzberg, MBBS PhDFRACP FRCPA, Sandra F. Deveridge, MDBSc,FRACP,FRCPA, Philip Arthur Rowlings, FRACP,FRCPA,MBBS,MS, Anthony K. Mills, MBBS, FRACP, FRCPA, Devinder S Gill, MBChB FRCPath MRCP, Peter G Bardy, MBBS, FRACP, FRCPA, Lynda Campbell, John F. Seymour, MD

Blood (2016) 128 (22): 338.

https://doi.org/10.1182/blood.V128.22.338.338

Published: 2016

Journal Articles

Interim Analysis of Lenalidomide Consolidation on Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

David Gottlieb, MBBS MDFRACP FRCPA, Thérèse Aurran, MD, Constantine S. Tam, MD, Mary Sartor, PhD, Rémi Letestu, MD PhD, Dennis Carney, Gavin Cull, MBBS DM FRACP FRCPA, Vincent Levy, MD PhD, Veronique Leblond, MD PhD, Marie Christine Bene, Andrew Budniak, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Florence Cymbalista, MD PhD

Blood (2016) 128 (22): 2053.

https://doi.org/10.1182/blood.V128.22.2053.2053

Published: 2016

NARROW

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Receiving Ibrutinib on the Phase 3 ASPEN Study ≥1 Year After Transitioning to Zanubrutinib

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma

Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (Cbl+G) As Front-Line Therapy

Effect of Rituximab in Primary Central Nervous System Lymphoma - results of the Randomized Phase III HOVON 105/ALLG NHL 24 Study

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma

Prognostic Factors and the Impact of Frontline Therapy in Peripheral T-Cell Lymphoma: A Multicenter Australian Study

High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Interim Analysis of Lenalidomide Consolidation on Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only